Shares of Haemonetics (HAE) have gained 2.4% over the past four weeks to close the last trading session at $86.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $112.17 indicates a potential upside of 30.1%. The average comprises six short-term price targets ranging from a low of $94 to a high of $125, with a standard deviation of $10.87. While the lowest estimate indicates an ...

CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has ser ...

BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and the first commercial European procedures for the SavvyWire® PreShaped Pressure Guidewire. The SavvyWire guidewire is the world's first and only sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI), designed to improve procedural efficiency with p ...

Core Insights - Haemonetics Corporation has received CE Mark certification for its SavvyWire guidewire, which is the first sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI) [8] - The SavvyWire guidewire is designed to enhance procedural efficiency by providing predictable wire performance, hemodynamic measurement, and left-ventricular pacing capabilities [8][10] - The first commercial procedures using the SavvyWire guidewire were successfully performed in Europe, specifically at CHU Bordeaux in France and Catharina Ziekenhuis Eindhoven in the Netherlands [4][8] Company Overview - Haemonetics is a global medical technology company focused on delivering innovative medical solutions aimed at improving patient outcomes [8][11] - The company has expanded its product portfolio with the acquisition of OpSens Inc. in December 2023, which included the SavvyWire guidewire [4] - Haemonetics aims to leverage its global commercial infrastructure to enhance access to critical interventional technologies across Europe, the Middle East, and Africa [5] Product Features - The SavvyWire guidewire allows for multiple procedural steps over the same guidewire, reducing the need for device exchanges and enabling continuous monitoring of cardiac hemodynamics [10] - It is engineered to support reliable left-ventricular pacing without the need for additional devices or venous access, streamlining the TAVI procedure [10] - The guidewire's capabilities are expected to raise the standard for hemodynamic measurements during TAVI, allowing for immediate procedural decision-making by physicians [11]

Haemonetics (HAE) is scheduled to report first-quarter fiscal 2025 results on Aug 8, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of 90 cents surpassed the Zacks Consensus Estimate by 2.27%. The Zacks Consensus Estimate for EPS of $1.03 indicates a year-over-year decline of 1.9%. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Hospital revenues in the fiscal first quarter are once again expected to hav ...

Core Insights - Both Haemonetics (HAE) and Boston Scientific (BSX) have a Zacks Rank of 2 (Buy), indicating positive earnings outlooks for both companies [1] - HAE has a P/B ratio of 4.77, while BSX has a P/B ratio of 5.71, suggesting HAE may be more attractively valued [2] - HAE's Value grade is B, compared to BSX's D, indicating HAE is viewed more favorably by value investors [5] Valuation Metrics - HAE has a forward P/E ratio of 19.75, significantly lower than BSX's forward P/E of 33.72, indicating HAE may be undervalued relative to BSX [8] - HAE's PEG ratio is 1.65, while BSX's PEG ratio is 2.69, further supporting the notion that HAE offers better value based on expected earnings growth [8] Investment Considerations - Investors in the Medical - Products sector may find HAE to be a superior value option compared to BSX based on the discussed valuation metrics [6][9]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. It also includes access to the Zacks Style Scores. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. The Style Scores are broken down into four categ ...

Within Plasma, revenues revenues grew 6% in the fourth quarter of fiscal 2024, driven primarily by disposable volume and software. The collections environment in the United States continued to be favorable, with disposables growing 4% in the quarter and 13% in fiscal 2024. Excluding the effects of the Consolidated Screening List's (CSL) U.S. Transitional supply agreement, the company's core plasma business is projected to deliver additional growth of 8% to 12% in fiscal 2025. Other Key Picks MEDP's earnings ...

Core Insights - The medical sector is gaining attention as investors seek defensive investments, particularly in health-related services [1] - The Zacks Strong Buy list currently includes 30 medical stocks, with Halozyme Therapeutics (HALO) and Neurocrine Biosciences (NBIX) being recent additions, both showing significant price performance over the past year [2][11] Company Performance - Neurocrine Biosciences is projected to see total sales growth of over 15% in FY24 and FY25, with estimates exceeding $2 billion, and EPS expected to increase by 71% in 2024 to $4.22 [8] - Halozyme Therapeutics is expected to have a 41% increase in EPS this year to $3.90, with FY25 EPS projected to rise by another 23% [12] - Haemonetics has shown a 30% increase over the last two years and a 141% gain over the past decade, with expectations of double-digit EPS growth in FY25 and FY26 [13] Valuation Metrics - Halozyme is trading at a forward earnings multiple of 13.5X, while Haemonetics is at 18.4X, which is below its decade-long high of 53.8X [12][13] - The medical sector is characterized by strong growth potential and favorable valuations, making it an attractive area for investment [10]

Core Viewpoint - Haemonetics (HAE) shows potential for significant upside, with a mean price target of $112.17 indicating a 33.2% upside from its current price of $84.21 [3][4]. Price Targets - The average price target consists of six estimates ranging from a low of $94 to a high of $125, with a standard deviation of $10.87, suggesting a moderate agreement among analysts [4]. - The lowest estimate indicates an 11.6% increase, while the highest suggests a 48.4% upside [4]. Analyst Sentiment - Analysts have recently shown increased optimism regarding HAE's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [6][12]. - The Zacks Consensus Estimate for the current year has increased by 0.4% due to one upward revision and no negative revisions in the last 30 days [13]. Zacks Rank - HAE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [14].